STM JOURNALS

Research & Reviews: Journal of
Oncology and Hematology

ISSN: 2319-3387
Volume 15, Issue 1, 2026
January–April
DOI (Journal): 10.37591/RRJoOH

https://journals.stmjournals.com/rrjooh

Review RRJoOH

Uncontrolled Cell Growth and Human Health: A Comprehensive Exploration of Cancer

V. Basil Hans*

Abstract

Cancer is a diverse category of diseases defined by the uncontrolled proliferation and spread of aberrant cells. It remains the major cause of morbidity and mortality worldwide. This article presents an overview of the various forms of cancer, such as carcinomas, sarcomas, lymphomas, and leukaemia, emphasising their distinct causes, symptoms, and risks. Early detection and diagnosis are emphasized as key to enhancing treatment outcomes. The article further provides an in-depth discussion of the wide spectrum of therapeutic remedies and treatment modalities currently employed in cancer management. Conventional treatment approaches, such as surgical excision, chemotherapy, and radiation therapy, are explained in detail, highlighting their roles, indications, and limitations in different stages and types of cancer. In addition, the article explores advanced and emerging treatment strategies, including immunotherapy and targeted therapy, which aim to enhance treatment precision by selectively attacking cancer cells while minimizing damage to normal tissues. Novel approaches, such as gene therapy and personalized medicine, are also examined, emphasizing their potential to tailor treatments based on an individual's genetic profile and tumor characteristics, thereby improving clinical outcomes. Furthermore, the article addresses the importance of lifestyle modifications and preventive measures, including healthy dietary practices, regular physical activity, avoidance of tobacco and excessive alcohol consumption, and early screening programs, in reducing cancer risk. By integrating recent scientific evidence and ongoing advancements in cancer research, this article aims to provide readers with a comprehensive understanding of cancer types, current therapeutic options, and evolving strategies for effective management and potential cure.

Keywords: Cancer, types of cancer, cancer treatment, early detection, preventive measures

INTRODUCTION TO CANCER

Cancer is a wide word for a group of disorders characterized by uncontrolled cell proliferation. Cancer develops from normal cells via a process known as transformation. Transformation refers to alterations in a cell that alter the expression of genes that control normal cell proliferation and differentiation. Cells undergo transformation, acquiring a variety of particular genetic and epigenetic changes that encourage unregulated proliferation. Tumor cells may exhibit various distinguishing traits that allow them to develop, survive, and proliferate [1–4].

***Author for Correspondence**
V. Basil Hans
E-mail: vhans2011@gmail.com

Research Professor, Department of Management and Commerce, Srinivas University, Mangalore, Karnataka, India

Received Date: January 16, 2026
Accepted Date: February 09, 2026
Published Date: April 05, 2026

Citation: V. Basil Hans. Uncontrolled Cell Growth and Human Health: A Comprehensive Exploration of Cancer. Research & Reviews: Journal of Oncology and Hematology. 2025; 15(1): 1–23p.

The term cancer refers to a wide range of disorders, the majority of which are characterized by malignant tumors. Cancers do not only develop in visible organs in the carcass, but also in widely dispersed and inaccessible tissues, including haematopoietic cells and the iris of the eye. Cancer is a pathological condition classified as neoplasia. Neoplasia denotes "new growth," implying that the tumor is producing new tissue. In general, the term "tumor" refers to both benign and malignant neoplasia, whereas cancer refers only to the malignant variety. Neoplasms or tumors are

© STM Journals 2026. All Rights Reserved

growths that are typically characterized by a disruption of normal cell control. In most cases, cancer is caused by genetic abnormalities that govern cell growth or apoptosis. Such transformation is typically a multistep process in which cells collect genetic changes that propel them through different stages. Importantly, cancer is much more than a basic disease of uncontrolled growth; it is defined by a variety of pathophysiological changes that allow tumor cells to expand inexplicably. This involves preventing apoptosis, maintaining proliferation, replicative immortality, angiogenesis, invasion, and metastasis [5–7].

Cancer is the second biggest cause of mortality in the United States, with an anticipated 606,880 deaths in 2019. There will be some rare inherited cancer susceptibility syndromes among these projected new instances, but most new cancer cases will be random. This refers to cases where no family history of the disease is present. In the case of sporadic malignancies, normal somatic cells undergo genetic and/or epigenetic modifications that influence the expression of the affected genes. As a result, it is possible that somatic DNA changes play a role in cancer [8–10].

UNDERSTANDING CANCER

Cancer encompasses a wide range of disorders marked by uncontrolled cell proliferation. Cancer initiation and progression are generally caused by significant genetic anomalies, which include down-regulation of tumor-suppressing genes and up-regulation of tumor-promoting genes. The first cancer case was documented in 1845 by a surgeon at the Royal Infirmary in Edinburgh. Since then, we have steadily gained a fundamental grasp of cancer biology and pathology. With rising societal income and population living standards, the prevalence of cancer has increased dramatically, posing a severe threat to human health [11–14]. In the United States, cancer is still the second largest cause of mortality, trailing only heart disease. To address these worrisome mortality rates, the National Cancer Act of 1971 was enacted in the United States. The pros and cons of many modern approaches to cancer control from three regions of the world, namely North America, Europe, and Asia (particularly China), were summarized with the goal of deepening our understanding of cancer biology and accelerating the development of more effective cancer therapeutics. Because of the tremendous work of all researchers and clinicians dedicated to better understanding cancer biology and developing novel therapeutic procedures, the eight basic hallmarks of cancer have been detailed in depth, and the corresponding targeting strategies have been examined. As a result of current therapies, numerous cancer forms, including non-small cell lung cancer, hepatocellular carcinoma, breast cancer, multiple myeloma, and others, have experienced longer survival times. Cancer is ubiquitous and affects everyone's lives. It kills around 5000 people worldwide each day. With the rapid advancement of next-generation sequencing technology, whole genome sequencing and whole exome sequencing are predicted to properly determine cancer susceptibility to selected medicines. Unfortunately, not all hospitals can afford such technologies and associated bioinformatics analysis, and appropriate medications are not always available. Liquid biopsy provides a new source for comprehensive genomic profiling of multiple tumors based on pooled cfDNA fragments liberated into the blood circulation system, resulting in a convenient tissue-agnostic diagnostic method with a feasible inline platform OncoCiDia, which is a massively parallel and quantitative assay based on phosphorescence decay timing identification [15–18].

What Is Cancer?

Cancer is a group of diseases characterized by uncontrolled cell proliferation. Most of these disorders demonstrate aggressive phenotypic features such as abnormal proliferation, unrestrained invasiveness, persistent angiogenesis, and immune evasion. Tumorigenesis and tumor formation are strongly associated with two types of genes: tumor-suppressing genes and tumor-promoting genes. Tumor-suppressing genes, also known as oncogenes, promote cell proliferation and survival. Tumor-promoting genes, also known as anti-oncogenes, suppress or decrease cell proliferation and survival [19–20].

The combination of a specific number of tumor-suppressing gene down-regulations and oncogene up-regulations is recognized as the start of carcinogenesis. Alternatively, several pro-carcinogenesis

© STM Journals 2026. All Rights Reserved

genes existed throughout the early stages of tumorigenesis. Genetic mutations typically cause amino-acid alterations in gene products, resulting in a gain of function. Down-regulation of tumor-suppressing genes and/or up-regulation of tumor-promoting genes alters cell behavior and phenotypes [21].

Cancer is one of humanity's oldest diseases, with records dating back to 1500 B.C.E. in The Edwin Smith Papyrus. Following the passage of the National Cancer Act in 1971, significant effort has been made to better understand the biology and pathology of malignancies, resulting in the development of more effective cancer therapies. In recent decades, highly ethical approaches have significantly enhanced the efficacy of clinical medicines like surgery, radiation, chemotherapy, anti-angiogenesis, and other types of targeted therapies that target both oncogenes and tumor microenvironments. As a result, preclinical and clinical therapeutic research efforts have yielded major advances in the treatment of a wide range of cancer types. For example, tailored medicines have extended the lives of practitioners infected with acute promyelocytic leukaemia and chronic myelogenous leukaemia by weeks to years, and in certain cases, healed them. A lot of effort needs to be done before every cancer kind may be successfully treated [22].

How Cancer Develops

Cancer is a broad category of diseases caused by the uncontrolled growth or proliferation of aberrant and mutant cells in a particular region or organ of the body. Cancer cells grow uncontrollably, forming tumors that can infiltrate surrounding tissues and spread to other parts of the body. It is a leading cause of illness and mortality, accounting for over 20% of all fatalities worldwide. Tumors are classified into two types: benign (do not metastasize or invade tissues) and malignant (also known as cancers), which invade and metastasize to neighboring tissues. Cancer cells metastasize to distant organs and tissues, generating secondary tumors. If left untreated, cancer frequently progresses to serious illness and death. One well-defined feature of cancer is an uncontrolled rise in cell proliferation. Multicellular organisms contain internal pathways that monitor the environment and regulate many cellular activities in a cell population such as proliferation, differentiation, and death. These internal pathways, known as tumor suppressor pathways, function as a brake on cell proliferation and division [23].

External cues, such as hormones, growth factors, and nutrients, can all encourage cell growth and division. Some malignancies can develop because of the failure of pathways that aid in the control of proliferation, or because of external signals stimulating cell division. There are various forms of cancer, some more dangerous than others. Melanoma, a type of skin cancer, kills around 8,000 people in the United States each year. Cancer is generally genetic, meaning it can be handed down from father to kid via the DNA within reproductive cells. Cancer at a young age is one of the most concerning symptoms, indicating that it may be inherited. Breast cancer is one of the most common genes associated with this inheritance. Women with BRCA1 and BRCA2 mutations are more likely to develop breast cancer and other extra mammary malignancies. Advanced stage breast cancer can be fatal and result in quick patient death. Cancer is primarily a result of aberrant cell proliferation that can spread to other sections of the body. These aberrant and mutant cells can form a new tumor, which frequently grows together into a mass or lump that may or may not be visible [24].

Common Myths About Cancer

Debunking cancer myths is an essential component of any educational process, both for cancer patients and others around them. A cancer diagnosis, like any other sickness, can spark a slew of misunderstandings that impede therapy and induce worry. Reassessing those assumptions helps alleviate anxiety and ensure that people get appropriate care. Attempts at education must also guarantee that persons who are overcome with fear or hope do not receive an overwhelming amount of information or unauthorized treatment alternatives, both of which could be harmful [25].

The most frequent cancer myths include those about how cancer begins and spreads, as well as the cancer death sentence myth. These beliefs can cause unnecessary anxiety and sorrow and may even lead to avoidance of prevention or treatment efforts. For example, believing that cancer is not contagious

© STM Journals 2026. All Rights Reserved

or infectious can cause a person to approach an interface or opportunity carelessly. On the other side, some beliefs, such as believing that a cancer diagnosis is a death sentence, might lead to a refusal to seek treatment. Myths about alternative medicines that are not supported by scientific data are also dangerous, as they may result in long periods of treatment during which the cancer grows unchecked. While all these unpleasant ideas have the potential to stifle progress towards therapy, they also demonstrate how fear and worry corrode individuals' mental health. Worrying tyrannically about cancer can cause stress, social rewiring, and other negative consequences for cancer therapy [26].

Another prevalent misconception is that consuming certain foods will treat cancer or prevent recurrence. This may cause some people to consume only "good" foods or to avoid eating "bad" foods for fear of the repercussions. This must be understood; dietary limitations have had a substantial impact on mood and comfort throughout treatment, and food is an essential component of daily life. Another common misconception is that eliminating sweets or food additives may slow the progression of cancer. To be clear, this myth is only partly true; sugary foods and additives are unhealthy, but they have not been linked to cancer. These myths are linked to the previous one because they create false optimism (e.g., eating can heal cancer or cause recurrence) and hence lead to emotional suffering and associated adverse effects [27].

Other equally frequent superstitions hold that cancer is the result of personal flaws – it is stigmatized and associated with immorality or social unacceptability. Others argue that cancer is simply a health concern, a disease of the wealthy, or an illness of the old. Such misconceptions limit our awareness of risk or exposure, potentially delegitimising pollution or healthcare disparity in general. In an age of pandemics, the notion that cancer is communicable or contagious may undermine acceptance of vaccinations, medicines, and societal policies addressing contagious diseases [28].

TYPES OF CANCER

Cancer is often termed for the site where it develops and is classified into the following groups of related tumors: carcinomas, sarcomas, leukaemias, lymphomas, melanomas, and rare cancers. Carcinomas, often known as solid tumors, are malignancies that develop in the epithelial tissue that covers the body's surfaces and lines its cavities. Carcinomas account for 85% of all malignancies in adults and are classified based on the type of epithelial cells in which they develop. Adenocarcinomas are derived from glandular epithelium; basal-cell carcinomas are derived from basal cells; squamous-cell carcinomas are derived from stratified squamous epithelium; and transitional-cell carcinomas are derived from transitional epithelium [29].

Sarcomas develop from embryonic mesoderm and are made up of connective tissues like bone, cartilage, blood vessels, and adipose tissue. Sarcomas are classified into two types: germ-cell tumors, which often develop in the testicles or ovaries, and sex-cord stromal tumors, which originate in the connective tissues that manufacture and sustain sex hormones in the gonads. Sarcomas account for 1% of all cancers and are most seen in children and adolescents. Leukaemias develop from blood-forming tissue in the bone marrow and are distinguished by the uncontrolled proliferation of blood cells, particularly white cells. Six forms of leukaemia have been defined based on the time course of clinical symptoms and the types of blood cells that are most impacted by the disease [30].

Lymphomas are malignancies caused by immunoblasts or plasma cells that originate from lymphoblasts. There are two basic varieties, each with unique clinical characteristics and aggressiveness. Melanomas develop from melanin-secreting cells, which are typically derived from the ectoderm. Rare malignancies include neuroblastoma, retinoblastoma, astrocytoma, glioblastoma, and its anaplastic form. These malignancies develop in neuroectodermal tissues and are more common in infants and children than adults.

Carcinomas

Apoplexy, also known as apoplexia, is characterized by a sudden loss of consciousness as well as a loss of mobility or sensation in a section of the body, typically from a paralysed state. Apoplexy, in

© STM Journals 2026. All Rights Reserved

both popular and medical usage, refers to a cerebral haemorrhage. Apoplexy has two aetiologies: primary, which occurs spontaneously with vessel rupture or occlusion, and secondary, which is a result or complication of other diseases such as haemorrhage from aneurisms or tumors, thrombosis or embolism in the heart or pulmonary system. There are four generally recognized periods, to wit: the initial period, which extends from a few seconds to several hours, or until the utmost disturbance caused by the rupture has occurred; the stage of reaction, which bears a close resemblance to a febrile attack, characterized by fever, rapid pulse, and respiration for twelve or twenty-four hours; and the stage of recovery, during which the patient improves and finally becomes free of warning signs and symptoms of attack or An habitual vertigo sufferer would be susceptible to one of these, but not to death by apoplexy, even if the signs of total apoplexy appeared, but would subside and cease with the return to normalcy [31].

Sarcomas

These tumors are a rare but important cause of illness and mortality in children and young adults. Sarcomas are exceedingly diverse cancers that develop from mesenchymal tissues such as bone, cartilage, muscle, adipose tissue, vascular tissues, and peripheral nerve tissue. Sarcomas make up less than 1% of all cancers, although there are more than 15 different forms categorized by anatomy, histology, and genetics. Sarcomas can be found in any anatomical region, however some tumors are more common in specific areas; for example, synovial sarcomas and rhabdomyosarcomas are more common in the extremities, whereas desmoplastic small round cell tumors are more common in the abdominal cavity. Sarcomas typically develop spontaneously from mesenchymal stem/progenitor cells. Differences in mesenchymal stem cell lineage give birth to a varied range of sarcoma subtypes [32].

A variety of cancers can result from genetic changes in mesenchymal stem cells. The most common sarcomas in children are embryonic rhabdomyosarcoma, osteosarcoma, and Ewing's sarcoma. Rhabdomyosarcoma, the most common soft tissue tumor in children, develops from primitive mesenchymal stem/progenitor cells that show early skeletal muscle lineage markers. Cardiomyoblastic differentiation produces embryonal, embryonal fusion negative, and pleomorphic variations (predominantly in teenagers). Osteosarcoma and Ewing's sarcoma develop from distinct stem/progenitor cells that are hypothesized to be common in an early developmental window. Most paediatric cancers result from de novo genetic changes, which typically impact important developmental pathways (e.g., Rb, p53). However, the stem cell lineages from which they originate remain mostly unclear [33].

Leukaemia

Leukaemia is a haematopoietic malignancy characterized by the uncontrolled proliferation of blood progenitor cells, which can be myeloid or lymphoid, resulting in abnormal blood cell counts and clinical symptoms, such as anaemia, bleeding, and recurrent infection, among others. Leukaemias are typically characterized as acute, with a rapid onset and a short survival time without effective therapy, or chronic, having a more gradual onset and a better prognosis. There are two forms of acute leukaemia: acute lymphoblastic leukaemia and acute myeloid leukaemia [34].

Acute lymphoblastic leukaemia is a very heterogeneous cancer with diverse clinical, developmental, and molecular features. When the condition is diagnosed, there is a significant increase of white cells, specifically blast lymphocytes. These improperly circulating cells are caused by a halt in lymphoblast development, which is accompanied by severe chromosomal abnormalities. The age distribution shows that 75% of cases present before the age of six, and 90% before the age of fifteen. HLA typing to match the donor and recipient is now common. To speed up the identification of possible donors, tissue typing can be performed concurrently with the diagnosis [35].

Acute myeloid leukaemia is a group of disorders distinguished by the fast buildup of myeloid progenitors in bone marrow and peripheral blood. In contrast to acute lymphoblastic leukaemia, the clinical symptoms, biology, and treatment response are all distinct. Acute myeloid leukaemia is

© STM Journals 2026. All Rights Reserved

classified into five types based on blasts found in the peripheral blood smear and clinical history: de novo acute myeloid leukaemia, post-chemotherapy, pregnancy-associated, precursor B cell neoplasm, and myelodysplastic syndrome. There is alternative diagnosis to explore. A careful morphological inspection of the aspirate and/or touch preparation, along with immunocytochemistry, flow cytometry, or cytogenetics, is helpful in making the diagnosis [36].

Lymphomas

Lymphomas are lymphatic system cancers that can be identified by detecting neoplastic cells in lymph nodes. These neoplasms develop from lymphocytes or one of their progenitors, which are mature immune cells that protect the host from infectious pathogens. The lymphatic system of the head and neck consists of neck lymphatic nodes, Waldeyer's pharyngeal lymphatic ring, and lymphatic distribution throughout the salivary glands, thyroid, and deeper facial tissues. Lymphomas can arise in any part of the head and neck tissues. Non-Hodgkin's lymphomas (NHLs) are a diverse category of lymphocyte neoplasms that, together with Hodgkin's disease (HD), account for 65% of all invasive neck cancers. Most NHLs (85%) are B-cell neoplasms, notably of the big and high-grade variety. Fifty percent of NHLs occur in the head and neck region; primary illness is typically limited to the nasal canals, sinuses, salivary glands, pharynx, or orbit, with most cases exhibiting intra-nodal ipsilateral extension. Generalized lymphoma can also affect the neck. Malignant lymphomas of the head and neck are uncommon before the age of ten, but their prevalence rises dramatically afterward. The incidence curves for all NHLs climb with age, with a strong peak after 15 years. Their estimated frequency is 5–7 per million people. Most patients are in their second or fifth decade of life, however it can occur at any age. Non-Hodgkin's lymphomas of mucosa-associated lymphoid tissue (MALT lymphomas) can attack certain head and neck tissues as early as childhood. Primary mucosal lymphoma with MALT features is most likely a kind of indolent lymphoma that affects the salivary glands and, in rare cases, the nose. Intra-orbital lymphomas are uncommon in the eye and adnexa, excluding orbital lymphomas. These original instances are only slightly related to nasal cavity lymphomas. NHLs of the hard palate are uncommon and usually subsequent neoplasms. Lymphomas of the oropharynx, particularly tonsils, are mostly CD10+ B-cell follicular lymphomas. Primary nasopharyngeal lymphomas are mostly of the null type and are frequently associated with EBV infection [22–26].

Melanomas

Melanoma is a kind of skin cancer that develops in the melanocytes, which produce melanin, the pigment that gives the skin its color. Melanoma is the most severe form of skin cancer. It occurs when cells start growing uncontrolled. The specific cause of melanoma is unknown. However, UV radiation is a significant risk factor for melanoma. Having fair skin that burns readily, having many moles, or having atypical or dysplastic moles all enhance the risk of developing melanoma. Melanoma is the fifth most often diagnosed cancer in both men and women, with a one-in-33 lifetime probability (1 in 54 for men and 1 in 49 for women). People with pale skin, freckles, red or blond hair, a family history of melanoma, genetic problems, or those who are severely immune-compromized are more likely to get this malignancy. Melanoma can appear in a variety of sites, including the trunk and limbs, neck, and face [25–28].

Melanoma appears as a new spot and can occur anywhere on the body. However, it is most typically found in locations that have been exposed to sunlight. In women, this normally involves the legs, but in men, it is mainly the back. Melanomas can also develop in places that are normally not exposed to the sun, such as the palms of the hands, the soles of the feet, and the inside of the mouth and nose. Melanoma is diagnosed with a visual examination of the skin, followed by a sample if necessary. Melanoma and other skin cancers can be suspected based on their appearance. There are warning signals that certain changes in moles or skin could indicate malignancy [30–32].

Asymmetry

One half of the mole or lesion does not look like the other half; border irregularity: The edges of the mole are not smooth; color: The color is not the same all over or there are shades of tan, brown, and

© STM Journals 2026. All Rights Reserved

black or there are spots of pink, red, white, or blue; diameter: The mole is larger than a pencil eraser (more than 1/4 inch); or evolving: The mole changes in size, shape, or color. Knowing these warning signals will help guarantee that the changes are noticed and evaluated by a health care provider before they spread. Melanoma can usually be successfully treated if identified early enough.

Rare Cancers

Despite increased efforts in the field of uncommon malignancies, a shortage of data is hampering development. Because of their rarity, uncommon malignancies present hurdles for researchers examining their characteristics such as incidence and survival outcomes. They can, however, be addressed by using visualisations that allow researchers without statistical skills to study the data. Rare cancers are malignancies with an annual incidence rate of less than 6 new cases per 100,000 people. This study focused on NCI-designated rare malignancies. A summary of the computerized databases and tools utilized in rare cancer epidemiological studies is provided. Most databases are free and open to the public, allowing for more efficient use of these valuable data resources. Because unusual tumors are uncommon, they are frequently overlooked or grouped with more common tumors. For example, the NCI nomenclature comprises more than 220 main cancer types classified by original site, histology, and behavior, but the SEER registry systematically collects data on over 40 uncommon cancers. Several separate groups have used a shared rigorous methodology to study uncommon tumors throughout the last decade. Several research are discussed, including rare tumor incidence rates, population-based treatment patterns, and socioeconomic factors affecting rare tumor prognosis. Important issues with these approaches are also explored. RCCs include around 200 distinct malignancies with annual incidences of <6 per 100,000. In Europe, uncommon tumors make up 24% of all malignancies. In Japan, uncommon cancers make around 15% of all cancer cases. In the United States, uncommon cancers make almost 25% of all cancer cases. RCCs account for a significant share of the global oncology burden. In Japan, there are typically less than 100 patients per orphan malignancy per year. The rarity of unusual cancer patients creates challenges for clinical practice, including inconsistent diagnosis that hinder evidence-based care. Most orphan cancers lack well-organized clinical case databases, making it difficult to apply evidence-based therapy procedures to them [20–26].

SYMPTOMS AND DIAGNOSES

Cancer symptoms vary depending on the type and location of the tumors. The major symptoms described below have been classified according to organ and system. Changes in shape and tone are drastic. Swelling on the face or around the eyes. The voice becomes deeper. Drawing back the upper lip (or entire lip) and revealing the teeth. Constant mild temperature, with occasional flushes. Prostration with a faster pulse and increased thirst. Continuous heaping and strong bowel motion. Frequent loose movements. Tumor in any portion of the body that is visible from outside. Internal growth or swelling, as well as the appearance of raised, reddish lumps. Difficult urination, undecomposed pee, needle-like pain in the glans penis, and scalding and burning sensations while urinating. Pain in the thigh that lasts for an extended period, as well as pain in the knee or calf. Bleeding or erosion provides direct access to the stomach. Ulcers all over the body are incurable. The final stage of convulsions in any organ. Solid or fluid aggregates can accumulate anywhere in the body. Disease spreads from one organ or system to another. Obstruction of an artery, duct, or tube. Gangrenous, lockjaw, or asphyxia. The alleged cause is often not the true cause. Cancer patients may not exhibit any symptoms until the disease has progressed to an advanced stage. As a result, it is critical to expose a person with pre-cancerous signs to a thorough examination so that cancer can be discovered at an early stage, when it is still treatable surgically. As a result, it is critical to understand the symptoms and to conduct a self-examination or a doctor's examination of any symptoms that persist inexorably, as well as to establish a cancer diagnosis [30–36].

Common Symptoms

As the body's cells are damaged and grow uncontrollably, a person may suffer a variety of symptoms that vary by individual and fluctuate depending on the affected body part. Tumors that form within or near bones can cause abrupt, inexplicable pain, swelling, or discomfort in the affected bone or joint,

© STM Journals 2026. All Rights Reserved

leading to persistent or recurring pain in the back or abdomen. You may also notice a lump or swelling, trouble breathing, eating, or speaking, changes in bowel or bladder habits, and persistent fever, night sweats, or exhaustion. Furthermore, tumors growing in the chest, stomach, or pelvis can cause symptoms, such as persistent cough or bloody sputum, weight loss without dieting, or jaundice, in which the skin and eyes turn yellow, resulting in patchy or sore skin that changes color and shape, including moles that become asymmetrical, varied in color, larger than a pencil eraser, or thicker than the skin itself.

Many individuals attend for health check-ups and are unintentionally diagnosed before experiencing any symptoms. However, symptoms that continue despite change should normally prompt additional investigation. Any change that lasts more than a few weeks is potentially harmful. Symptoms that have been diagnosed but have dramatically changed or deteriorated in nature will also require additional attention. At the same time, not all people with the aforementioned symptoms develop cancer; for example, prolonged cough may be an indication of bronchitis or asthma. It is also crucial to note that not all the following symptoms will be present; some tumors will not exhibit any symptoms in their early stages.

Diagnostic Tests

Breast cancer is a breast tissue illness characterized by irregular cell division and aberrant growth. Tumors are made up of irregularly grouped cells. Tumors can include benign and malignant forms. Non-cancerous (benign) tumors do not spread to neighboring areas, but malignant (epithelial) tumors multiply improperly and may spread to healthy tissues nearby. The gland tissue in the breast is separated into lobules and ducts. Lobules are milk-producing glands, and ducts are tube-like structures that connect to lobules. Breast cancer cells can develop in lobules or ducts. Non-cancerous lobular or duct cell proliferation is known as lobular carcinoma in situ or ductal carcinoma in situ, respectively. Malignant lobule or duct cell development is known as infiltrating lobular carcinoma or infiltrating ductal carcinoma, respectively, and these malignancies can spread to surrounding tissues. Some tumors consist of both invasive and non-invasive diseases.

Breast cancer is diagnosed through screening, clinical examination, and imaging tests such as mammograms and sonography. In addition to traditional imaging, several imaging modalities for breast cancer staging include CT scans and ultrasonography. Breast MRI is used in conjunction with mammography for staging, particularly in preoperative evaluations and cases of invasive lobular cancer. MRI can be used to detect clinical contralateral and multifocal/multicentric breast cancer, as well as to evaluate ongoing treatment therapy, using contrast-enhanced T1-weighted images. Identimental metastasis occurs seldom in breast cancer, and it can be detected by CT and MRI. Mediastinal metastasis is less common in lobular carcinoma but more common in other forms, including infiltrating ductal carcinoma, tubulolobular carcinoma and papillary cancer. Due to potential confusion with post-treatment changes in mammography, post-surgical scar recurring illness may be misdiagnosed as a tumor. MRI can accurately distinguish between scars and recurring illness.

The Importance of Early Detection

Cancer is one of the most severe illnesses that has become a dreaded one, causing harm both physically and psychologically. Though much study is still being conducted to determine the aetiology, epidemiology, and pathophysiology of this illness, a comprehensive understanding of each kind of cancer remains lacking. Cancer is the second biggest cause of death in the United States and around the world, following cardiovascular disease. Cancer prevention research focusses on finding and altering lifestyle factors that contribute to the development of cancer. Cancer has a high probability of being cured if detected and treated early on. Carcinomas of the breast, cervix, colon, lip, mouth, throat, larynx, and skin are now being diagnosed in their presymptomatic, preinvasive stages, resulting in an area free of this lethal illness. Anal pap smears to detect anal canal preinvasive lesions have been implemented in a few centres serving high-risk patients in the United States. Never has the plea for “early detection”

© STM Journals 2026. All Rights Reserved

been heard with such zeal. Clinical staging has resulted in a unified nomenclature for clinical treatment assessments, hence enhancing communication.

There is widespread agreement that the clinical stage at the time of diagnosis is the most important predictor of recurrence and mortality in oral cancer patients. Multiple clinical and sociodemographic variables influence diagnostic time, including patient reluctance to visit a health-care professional due to limited access to health care, particularly in low-income individuals. According to studies, dentists and other health-care providers are in critical need of systemic educational updates in oral cancer prevention and early detection, as they are inadequate in providing oral examinations and detecting early oral malignancies. Clinicians can enhance patients' survival rates by detecting cancerous lesions at an early stage or treating precursor lesions (dysplasia) before malignant progression. Our poor capacity to distinguish between oral precancerous lesions at high risk of evolving to invasive SCC and those at low risk poses a significant obstacle for early detection of at-risk tissue. Thus, the prevention of oral cancer and its associated morbidity and mortality is dependent on the early recognition of oral precancerous lesions, which allows for histological investigation and subsequent therapy based on the stage of diagnosis. As a result, early detection and screening for oral cancer may reduce the disease's morbidity and death.

TREATMENT OPTIONS

Over half of current medical therapy is for cancer chemotherapeutic medications against malignancy, which are either experimental or commercially accessible, but are not included in this global survey of cancer treatment breakthroughs or are geared at a specific ailment. One intriguing aspect of this is the shifting nature of priority subjects. Three years ago, new medications were mostly concerned with inhibiting angiogenesis, but there appears to have been a steady return to renewed interest in nitroso compounds.

Current standard therapy with conventional methods is significantly variable for the numerous cancers recognized by clinicians. It is based on a complicated interaction between the type of malignancy, its location, the level of local and distant dissemination, and other co-morbid variables, particularly those unique to the patient. In so-called "curative" therapy, the average prognosis for patients with newly discovered operable disease ranges from 75% 10 to 90% cure in some forms of cancer to less than 5% for more chemically resistant cancers such as pancreatic carcinoma or pleural mesothelioma. There is a lot of hope that improvements in other sectors of research, some of which may seem more like science fiction, will produce results in the future.

Despite the increasingly sophisticated current advances in manipulation over increasing periods of time of existing treatment modalities, there is a growing awareness that these would be of limited value without the incorporation of surgical attempts to remove the bulk of the malignant tissue, curing fortunately, and improving the conditions for advanced cases, where the majority of the unmitigated coercive current treatment by other modalities is now used, despite the limit Much more has been accomplished by considering how to view and manipulate living tissues at finer levels than those examined by imagining the interplay of molecular device packings within cellular tissues, all carefully orchestrated by codified mechanisms, almost all of which are puzzling in detail.

It is critical to preserve the primitive forms of all material on this planet, both living and seemingly non-living, including crystals and molecules, which are elements of all currently known life systems. Whatever scientific and technological improvements are made, nothing can prevent them from reverting to primitive forms unless negative entropy is continuously introduced into the larger total. It will be demonstrated how such systems can mimic biological tissues and act as components of more complex systems at higher degrees of integration, comparable to those now called living due to current omissions in definitions of life. It is certain that considering systems from this perspective will inevitably yield new modes of appreciation for the multitude of properties of these systems, as well as simple means for

© STM Journals 2026. All Rights Reserved

quantifying and manipulating them, and thus new therapeutic developments for presently almost inauditable human societies.

Over the last century or so, there have been remarkable advances in cancer treatment using conventional techniques such as surgery, radiotherapy, and chemotherapy. More recently, with new understandings of the molecular features of oncogenesis, metastatic spread, cancer dormancy, and autoimmunity, there has been interest in the possible application of advancements in other fields of science to the treatment of cancer-related diseases. Most of these methods have remained hidden from contemporary academic medical understanding and have not been subjected to standard scientific evaluation. Selected chemical and physical treatments that are either in their early stages or on the verge of becoming practical will be reviewed. Conventional isopentrials utilising a cocktail of unique arrangements of commercially available mediators will be addressed, along with the naming of numerous such combinations already in use.

Surgery

Surgery is an important cancer treatment modality that encompasses a wide range of diseases such as the excision of localized tumors, palliation of unresectable tumors, and intracranial decompression of tumors with mass effect. Surgery generates trauma for the sufferer. Anaesthesia, blood loss, stress, and postoperative inflammatory reactions spread throughout the body and have consequences that go beyond the surgical site. Surgical treatment is now recognized as a crucial component of successful local and combination modality therapy for an increasing range of neoplastic illnesses. Similarly, interest in the connections between immunology and surgery has increased tremendously. The current review took the approach of gathering the available literature on perioperative immunity and surgery and summarising the implications that the accepted and evolving knowledge base has for the surgical treatment of cancer, including its rationale, barriers to effective applications, and consideration of its broader effects on outcomes, with an eye towards potential areas for future research.

Furthermore, immunobiology, namely the nature, function, and role of antigen presentation cells, is discussed in conjunction with the mechanisms that underpin strong cancer immunity and tolerance. A review of the current research on cancer surgery and immunity revealed differences in tumor resection, cancer as a wound healing signature, the temporal aspects of the immune response, and their translation into clinical trials. Immunology has experienced a remarkable epistemological paradigm change; clinical experience with tumors of the liver, prostate, and other organs has contributed considerably to updating the view that cancer is an immune system illness. As a result of the emphasis on surgical excision of primary tumors and/or nodes, neoadjuvant and adjuvant regimes with systemic immunologic modifiers, rather than just cytotoxic chemotherapeutic methods, are being reconsidered. Surgery is now widely recognized as the most common real-safe target treatment method. Integrating surgical excision with immunotherapy has shown promise in preclinical models, and breakthroughs in biomarkers will help further development.

Radiation Therapy

Radiation therapy, like X-rays, uses high-energy waves or particles to treat cancer. It accomplishes this by rendering the DNA in tumor cells unrepairable, ultimately leading to cell death. If cancer cells were treated with radiation, they would be unable to grow and form new tumors. It is crucial to understand the type of cancer because various types may require different doses of radiation and may be more likely to survive the therapy. Unfortunately, a radiation treatment speciality is limited since radiation dose and delivery parameters must be carefully controlled to minimize damage to adjacent healthy tissue such as skin or organs. These side effects of natural tissue damage might result in severe issues, including death. Furthermore, even if the radiation treatment was focused entirely on the tumor using multi-leaf collimators, the dosage supplied would need to be repeated every day for some time to ensure that the cancer would not spread. This is referred to as “fractions.” However, frequent therapy puts normal tissue at danger. Thus, extensive study has been conducted to determine not only how

© STM Journals 2026. All Rights Reserved

radiotherapy can improve the treatment of malignancies on its own, but also how it can be combined with medications, hormone treatment, immunological treatment, microenvironment alteration, or non-invasive imaging modalities. The implementation of these technologies to improve radiotherapy treatment is expected to boost the chances of long-term cancer-free life. To summarize, while radiation therapy's precision is important in cancer treatment, it also has trade-offs that should not be neglected, because destroying the adversary does not eliminate it.

Chemotherapy

Systemic chemotherapy refers to the employment of medications to combat cancer cells throughout the body. In this procedure, the entire or a portion of the body is treated to limit the number of malignant cells and to breast wall the uncontrol of other cells. Cancer grows in an improper and uncontrolled manner. These malignant cells have specific characteristics that distinguish them from normal ones. Chemotherapy uses antineoplastic drugs to treat the full or a portion of the body. These antineoplastic medicines include alkaloids, antibiotics, and chemicals that interfere with cell reproduction. Some of these agents are effective when used at the appropriate timing and dosage. In cancer chemotherapy, several groups of medications are utilized. Typically, a single agent is used at first, but if the response is incomplete, other levels of drug are added. Many anticancer medications are derived from microorganisms or synthetic sources such as nitroso and platinating compounds. A recent study found synergy between tamoxifene and diavermedes but antagonism with doxrobicin. However, natural medications have not yet emerged as a first-line cancer chemotherapy agent. There are numerous anticancer compounds derived from plant sources that have great potential for development as drugs against various types of cancer. Only a few trials have been conducted using randomized designs to determine the safety and efficacy of these plant-based anticancer medicines. Natural anti-cancer compounds used in conjunction to create a combination therapy cocktail are still under investigation, making it difficult to attribute their safety and efficacy to various cancer types. To achieve this goal, a patient's symptoms and all relevant literature containing the origin, efficacy, safety data, and clinical trial history of medications are carefully considered before developing a chemotherapy cocktail for this patient. This firm foundation for refining and modification became the usual treatment for patients with recurrences and resistance.

Immunotherapy

According to the National Cancer Institute, immunotherapy is a sort of cancer treatment that aids the immune system in fighting cancer. Immunotherapy either makes the immune system work harder or smarter, or it supplies the immune system with what it requires to function such as immune system proteins. Recently, researchers have paired immunotherapy with other standard treatments, yielding improved results. Clinical trials have shown that the combination of immune checkpoint inhibitors and hormone inhibitors is effective for breast cancer. Targeting tumor-infiltrating tregs is also a viable therapy option. Cancer vaccines increase immune response to tumor antigens, particularly when combined with immune checkpoint inhibitor treatment. Heat shock protein peptide vaccines have been proven to work well with immune checkpoint inhibitors. The FDA has approved chimeric antigen receptor (CAR) T cell treatment for blood cancers, which has since been expanded to include solid tumors. More potential CAR targets are being identified in various types of tumors. New CAR T cell designs may also avoid undesirable outcomes such as excessive toxicity. A better knowledge of the mechanisms underlying CAR T cell elimination and CAR targeting enhancement may lead to new treatment options for solid tumors.

Immunotherapy has been used to treat a variety of cancers, but its effectiveness remains restricted. Patients frequently develop resistance to treatment, so researchers are always looking for novel ways to increase immunotherapy response. The potential techniques based on tumor and immune system molecular biology will be discussed. Tumor-intrinsic factors, such as tumor mutational burden, expression of major histocompatibility complex, immunogenicity of neoantigens, ability to present antigens to T cells, expression of immune checkpoint proteins, and epigenetic alteration have all been investigated to identify biomarkers that are expected to lead to improved treatment strategies. Tumor-

© STM Journals 2026. All Rights Reserved

extrinsic variables, such as immune cell types, their differentiation and functional status, cytokine and chemokine production in and around tumors, and the gut microbial ecosystem, have all been demonstrated to regulate anti-tumor immunity. The implementation of a combinational method has demonstrated the efficacy of existing therapeutic choices and is expected to result in fresh alternatives. New technologies and tactics, including as massively parallel DNA manufacturing, virus-mediated targeted destruction, and artificial intelligence-based dosage and treatment order designs, will also significantly boost immunotherapy development.

Targeted Therapy

Cancer is the second biggest cause of death worldwide, accounting for approximately one out of every six fatalities. Radiation therapy, surgery, and systemic chemotherapy are the current cornerstones of cancer therapy, yet they all have limitations that restrict their effectiveness in the clinic. For example, high doses of cytotoxic agents cause toxicity in healthy tissues, resulting in well-known cancer therapy side effects such as nausea, hair loss, and myelosuppression (thrombocytopenia, leukopenia, and anaemia). This has resulted in the creation of medicines that selectively target tumorigenic pathways. Traditional cytotoxic chemotherapies often target quickly proliferating cancer cells, but they also target fast dividing healthy cells, resulting in the well-known side effects of chemotherapy. Targeted medicines aim to lessen these negative effects by acting more precisely.

Small-molecule inhibitors and monoclonal antibodies (mAbs) are the two main types of targeted anticancer medicines. Small-molecule inhibitors (≤500 Da) can pass through the plasma membrane and interact with receptors or intracellular signalling molecules. Most small-molecule inhibitors are intended to interfere with enzymes, particularly receptor tyrosine kinases (RTKs). Several small-molecule inhibitors have been approved by the FDA for cancer treatment, including inhibitors of tyrosine kinases (TKIs), HER2, EGFR, and VEGF. Other small-molecule inhibitors currently in clinical trials target intracellular pathways such as BRAF and Akt. One of the most notable therapeutic successes was the invention of imatinib, a BCR-Abl inhibitor that was approved by the FDA in 2001 for the treatment of chronic myelogenous leukaemia.

Treatment options for NSCLC are mostly determined by tumor grade, size, and location. Surgery, chemotherapy, radiation therapy, and targeted therapy are all approved treatments for NSCLC. Adjuvant therapy with the targeted medication osimertinib may be an option for patients whose cancer cells contain mutations in the EGFR gene. In this situation, after lung cancer surgery, patients will most likely undergo chemotherapy and immunotherapy to prevent cancer growth. Before beginning treatment for stage IVB tumors that have metastasized throughout the body, the cancer cells will be screened for certain gene alterations. If one of these genes is mutated, the first treatment option will most likely be a targeted therapy medicine.

Clinical Trials

In recent years, cancer drug analysis has made significant progress towards more practical, precise, and less invasive cancer treatments in clinical trial research. Currently, the most common entries focussing on cancer therapies include the terms stem cell, targeted therapy, immunotherapy, and gene therapy because they are extremely promising and effective. Cancer is one of the most challenging areas for discovering novel drugs and therapies. This summary covers the most recent updates on cancer kinds, medications, and expected adverse effects, target-based techniques, including oncoproteins targeted, CD that leads to the production of immune effector cells, and use of optical and radio-labeled catalysts. Furthermore, tumor-shaped nanoparticles are explored in terms of maximum and minimum chemical load. Surface coating with polymers likely reduces the dual targeting techniques of cancer methotrexate conjugator candidates. In addition, longitude development and drug control are explored.

Cancer refers to a wide range of disorders characterized by unregulated and often aggressive cell proliferation. Although the first cancer case was officially reported in 1845, it has taken decades to gain a thorough grasp of its biology and pathology. Population-based cancer registries indicate that there

© STM Journals 2026. All Rights Reserved

will be new cancer cases and cancer-related deaths in the United States in 2019, making it the second highest cause of death. Subsequent global assessments found a total incidence and cancer mortality. To combat the increasing mortality rates, the National Cancer Act was enacted in the United States with the goal of improving understanding of cancer biology and, ultimately, prompting the creation of more effective cancer therapies. New mechanistic insights into the development and progression of various cancer types, diagnostic and prognostic biomarkers, as well as novel cancer drugs and drug combinations, have been discovered and are being developed because of advances in translational science and cross-disciplinary collaborations, ushering in a cancer treatment revolution. Many cancer forms, including non-small cell lung cancer, hepatocellular carcinoma, breast cancer, and multiple myeloma, have seen improved survival rates thanks to breakthroughs in clinical treatments and management. As a result, it is appropriate to summarize the present landscape of available and emerging cancer treatments, including their benefits and drawbacks, as well as prospects. The innovative strategies for early cancer detection and their implementation in clinical practice are also reviewed, as are unmet needs and future views.

COMPLEMENTARY AND ALTERNATIVE REMEDIES

Complementary and alternative treatments (CAM) are used to diagnose or treat health issues that are not covered by mainstream medical techniques. In general, “complementary” therapies are those that a person employs in addition to conventional medicine, and “alternative” therapies are those that a person selects over normal medical treatments. Many cancer patients seek CAM treatments. Some people use them to help treat their cancer, while others use them to relieve cancer-related discomforts or symptoms, as well as treatment side effects. Although there is no official or approved list of CAM therapies, many people associate the term with herbal and other botanical cures, dietary supplements, special diets, mind-body therapies, and energy therapies. This section discusses herbal cancer treatments, nutritional measures to reduce risk or improve treatment effectiveness, mind-body techniques for better cancer coping, and acupuncture for pain relief and other treatment side effects.

Herbal Remedies

Herbs including liquorice, ginseng, ginkgo, and echinacea have been utilized to treat ailments since ancient times. Modern herbal therapy grew in popularity as people were more open to using herbal medicines and nutritional supplements to address common disorders. Many herbal products were studied in controlled research or clinical trials to help improve the immune system, which is critical for cancer prevention and therapy. Some positive outcomes were observed. Liquorice and green tea extract, for example, were demonstrated to induce apoptosis in multiple cancer cell lines and decrease the growth of transplanted melanoma in a mouse metastasis model. The patients with liver cancer were then treated with amitriptyline, a tricyclic antidepressant, and fluoxetine, a selective serotonin reuptake inhibitor. Some patients experienced tumor-inhibiting effects.

Herbs, such as grape seed extract, milk thistle, ginseng, and green tea polyphenols, offered several stories of purported cures. Nonetheless, most therapies have not been tested in double-blind, placebo-controlled trials. Some commercial goods can interfere with chemotherapy treatments, increase the toxicity of anticancer medications, and even jeopardize cancer treatment. Patients who take herbal products must notify their physicians. A statewide study of chemists indicated that many could advise patients regarding herb-drug interactions, but ambiguity was also common. Only 22 indigenous plants that are clearly useful in cancer treatment were cited.

Nutritional Approaches

The importance of nutrition and a healthy diet in the onset and progression of cancer, as well as the success of cancer treatment, has been extensively researched. Both avoiding nutritional deficits and excesses were emphasized, as the fateful more than 100 previous attempts to build a diet based solely on anticancer medicines must have missed some vital ingredient.

There are numerous epidemiological surveys including hundreds of thousands of people from several continents, including countries, that show more than one association for each food component. Various

© STM Journals 2026. All Rights Reserved

viewpoints are published, claiming that vegetables, fruits, or dairy substitutes are traditionally or newly anti-cancerogenic only in certain communities, countries, or even nations. No safety claim provided by the makers was satisfied. Public health organisations recommend eating at least five servings of fruits and vegetables every day, as well as supplementing with vitamin E, omega-3 fatty acids, and three cups of green tea. Nutritional deficits must be avoided to maintain immunity, and a high-fiber, low-fat, moderate-protein diet is required to improve treatment. Dietary supplements may also be suitable.

Herbal Remedies

Medicinal herbs used for cancer treatment and their outcomes in modern practice A scoping review was conducted to assess the medicinal herbs that have been utilized in cancer treatment utilising the framework. The review identified plants that were specifically used to treat cancer, as well as one herb that was used to alleviate related symptoms. Completed investigations and literature evaluations on the outcomes of these herbs were also examined to determine their popularity in modern practice. Furthermore, investigations investigating the chemistry of these herbs were evaluated, revealing evidence of important medicinal components for modern therapy. Aside from therapeutic benefits, ethnobotanical and cultural uses of the herbs were discussed to help explain why they are so popular today. The findings demonstrated a strong interest in cancer prevention among herbalists in the literature, but only a few completed research investigating the therapies. The most often reported herbs were Curcuma longa and Ginkgo biloba, both of which had therapeutic applications for cancer treatment and symptom control. Ginkgo biloba has also had numerous recorded outcomes in modern practice, with nutrient supplementation with fish oils, vitamin E, curcumin, and herbs, such as Ginkgo, demonstrating promise in improving quality of life for patients receiving chemotherapy. Calendula officinalis and Hydrastis canadensis had anecdotal evidence in traditional and modern use as wound healing herbs, with a few studies suggesting improved recovery following surgery. Echinacea purpurea, Uncaria tomentose, and Astragulus membranaceus all attempted to boost immune function/system, with little evidence to support their current use. Uncaria tomentose and Curcuma longa have been demonstrated to minimize the chance of circulating cancer cells, which would be very interesting. Eleutherococcus senticosus and Panax ginseng strive to restore the body to health before continuing cancer therapy, and both have anecdotal evidence of stress alleviation. Cannabis sativa has been shown to inhibit primary cancer growth by reducing angiogenesis; however, no documented evidence of this application exists in practice. Finally, Viscum album is a safe and effective cancer treatment that helps to reduce chemotherapy-related toxicity.

Nutritional Approaches

In recent decades, there has been a growing interest in herbal therapy, nutraceuticals, and supplements for cancer patients. The growth in case reports of cancer therapy and even regression in the presence of aggressive and advanced malignancies using natural medicines has piqued the interest of both the public and the scientific and medical communities. Mistrust of conventional cancer treatments has led a segment of the population to view alternative medicine as their only hope for survival, with topical oils, tonics, herbal pills, vegetable juices, and other commercial herbal preparations marketed with false claims of cancer cures. Organic food stores, speciality cancer centres, and pharmacies offer discounts and possibilities to purchase nutraceuticals, with proof of DAB- and CAV-negative cancer keratoacanthomas splitting apart after a few days of prayer and high-dose nutraceutical use. There have been worrying reports of galactogogic drugs being administered to infants, as well as custard apple seeds and morphinocarcotic plants being licensed for herbal therapy in children with chronic myeloid leukaemia and lymphomas. Evidence supports the basic role of some plants, such as the thorny shrub Ammi visnaga, in eradicating exophytic growth in late-stage cancers (based on external use) and of some Celosia family members in controlling the most aggressive types of solid tumors (using pulp extract for preparation).

A rising number of websites redirect and/or refute incorrect claims about natural products, herbs, alternative medical approaches, or mainstream medicine therapies. Potential conflicts of interest can arise in such situations in academic institutions with personnel involved in both industry-oriented and

© STM Journals 2026. All Rights Reserved

alternative approaches, because of patenting an indeterminate composition and activists claiming cherry-picking or omission of positive/negative findings from published publications. Well-controlled studies and meta-analyses of alternative medicine approaches aimed primarily at cancer therapy must be pushed, as these are currently fraught with bias due to the enormity of financial loss sustained by alternative cancer treatments. To tackle this issue, certain journals have begun rigorous peer review, and anyone willing to buy time owing to a "desperate" situation should read the disclaimers for alternative medicines. Standard practice procedures, such as chemotherapy and/or X-ray radiation exposure, increase the demand for nutritional supplements. Nutritional supplements eaten during conventional therapies appear to influence elements of cancer treatment result, therefore, calls for a consensus advice cannot even be considered. Given the prevalence of unidentified and unmonitored dietary supplements among many patients, examining their use to obtain an advantage in patient treatment is justified.

Mind/Body Techniques

Mind–body medicine (MBM) is a developing field that emphasizes the interconnectedness of the mind and body. It covers techniques and processes that allow the mind to alter bodily functions. Patients with breast cancer are increasingly using meditation, yoga, hypnosis, and biofeedback. MBM research in cancer has also developed significantly, however most studies to date have focused on breast cancer patients. The potential for MBM to alleviate cancer-related discomfort appears to be significant, while larger and more rigorous research are required to confirm the effects of several mind–body approaches on cancer symptoms and treatment.

Mindfulness-based stress reduction has been found to help patients comprehend and regulate their stress reactions. Many patients get a more conscious understanding of their lives because of personal experiences with pressures and sickness. As an addition to standard medical therapy, a mixed cancer population received a mindfulness-based stress reduction (MBSR) program. Participants in MBSR reported reduced levels of mood disturbance and distress than those receiving standard therapy. Furthermore, MBSR participants reported significant increases in mood, sleep quality, and fatigue. Studies including MBSR therapies in breast cancer patients have also found reduced stress symptoms, lower cortisol levels, and increased quality of life. A recent randomized controlled trial of a 6-week MBSR program for early-stage breast cancer survivors found that, when compared to a waitlist control group, women who completed the program experienced significantly lower levels of anxiety, depression, and fear of recurrence, as well as improved physical functioning.

Individual studies in cancer patients have found that practicing traditional holistic yoga improves stress, anxiety, emotional well-being, sleep, mood, depression, exhaustion, symptom intensity, and quality of life. Across 16 research, the majority of which were class III-1 randomized controlled trials, Yoga appeared to be an effective complementary medicine (CM) intervention for psychological distress, exhaustion, sleep problems, and physical and quality of life outcomes. The yoga therapies typically lasted 6 to more than 24 weeks and included sessions ranging from 75 to 120 minutes. Classes were normally held once or twice a week. It is still to be discovered whether the duration of the intervention or the frequency of classes matters.

Acupuncture

Cancer is the second biggest cause of death in the United States, with 41.24% of men and women being diagnosed with some kind of cancer during their lives. Despite breakthroughs in early detection, cancer is still a lethal disease when discovered at a curable stage. Every year, around 12 million new cases are diagnosed in the developed world, with 5 million developing symptoms that require palliation. While the need for therapy grows as life expectancy increases, active treatment is frequently overlooked, and a few years of constant palliation are required to reduce symptoms and extend quality of life. In 1906, an organisation was established to combat cancer. Modern therapeutic procedures, such as medications, surgery, and radiotherapy, have significantly enhanced life expectancy, yet management of cancer-related pain remains limited. Between 70% and 80% of cancer patients endure

© STM Journals 2026. All Rights Reserved

pain during their disease, and in most countries, 90% have access to insufficient pain relief. They may experience somatic pain because of a malignant neoplasm invading their tissues or from pressure on visceral organs. In contrast, discomfort might result from adverse effects of typical treatment modalities such as medications, surgery, radiation, and chemotherapy. Opioids are the primary treatment for cancer pain, and in a study of 1,600 cancer patients, up to 20% were opioid resistant. Many patients refuse narcotic-based therapy due to side effects include constipation, drowsiness, and respiratory depression. Furthermore, because treatment-related pain is frequently acute and may be handled with routine care, many oncologists avoid therapy medications that have significant adverse effects. Limited understanding of the issue is also a barrier, with 85% of oncologists believing that cancer pain treatment procedures were appropriate.

Practitioners must keep in mind that the use of complementary therapies to address comorbidities in older persons, such as depression, musculoskeletal problems, cancer, and chronic pain, is prescriptive and not based on assessments of mental status, cognition, or mood. Almost 60% of patients who used complementary and alternative medicine had addressed this trend with their oncologist, and many believed it increased chemotherapy efficacy and reduced adverse effects. Although medication is not usually used to treat depression in cancer patients, complementary and alternative medicine is becoming more popular as a symptom alleviation option. Acupuncture and meditation workshops are popular among individuals seeking holistic care, but despite their growing popularity, little study has been conducted on cancer pain. However, two case series involving only six patients merit examination. This report describes a case series of three cancer patients who had acupuncture for chronic unbearable pain. Data were gathered using the Linear Analogue Scale Assessment and the Health-Related Quality of Life. Pain medication was increased, lowered, or stabilized based on the time interval, and patients reported their cancer-related pain, neuropathic pain, health improvements, and subsequent modifications in conventional treatment.

LIVING WITH CANCER

Cancer can occur in practically any place or system of the body. The neoplasm may appear as a brain, breast, prostate, lung, or other sort of tumor. All forms can be malignant and develop into cancer. In addition to the underlying disease, cancer cells can spread to distant areas via the lymphatic and circulatory systems. Cancer at this stage can spread throughout the body, typically to the liver, bones, lungs, and brain, resulting in a wide range of symptoms and problems. Cancer and its repercussions can have a wide-ranging impact on a patient's quality of life, including physical, social, psychological, and occupational factors. Quality of life is a multifaceted concept that includes reported sentiments and/or beliefs regarding health, functional abilities, and psychological health. Various illness sites or consequences might impair every area of quality of life, and treatment approaches have a negative impact on most domains. The topicality and complexity of the subject matter, together with the range and quality of available material, make it difficult to develop any unique recommendations or guidelines.

The medical management of cancer patients has traditionally concentrated on the delivery of cytotoxic medicines to potentially eliminate or reduce the tumor burden. Such treatment regimens can be personally or socially demanding, and while they are safest and most effective in a hospital setting, they frequently need protracted hospitalisation. Such treatments can be exceedingly harmful to the body, disrupting regular professional and social habits. As a result, the timing of referring patients for rehabilitation, as well as the form or type of therapy, must be carefully considered. It might be claimed that there are two types of patients that require rehabilitation guidelines: those who have a poor response to treatment and whose condition progresses significantly despite therapy.

Treatment interruption or failure may cause or contribute to deterioration of psychosocial health. This is the moment when coping strategies are under increased stress, and a wide range of physical and mental symptoms and worries emerge with increasing severity. However, some patients may not fit into the conventional rehabilitation approaches. There is undoubtedly a need for input when rehabilitation

© STM Journals 2026. All Rights Reserved

shifts to community or palliative care, ideally from a multidisciplinary team to handle the complexities of conditions and scenarios. There is also a need for pre- and post-treatment guidelines that specify what to advise, recommendations, rehabilitative treatments, and the type of input required.

Coping Strategies

Cancer and its treatments raise psychological and societal difficulties. Patients are concerned about cancer recurrence, side effects, and consequences from cancer treatment. Patients can experience significant social issues such as losing their jobs, family support, and social standing. A patient's religious beliefs, financial situation, and emotional well-being will all have an impact on how they deal with cancer and its treatment. To provide holistic nursing care, it is necessary to understand cancer patients' coping methods. Patients' most prevalent coping mechanisms included acceptance, emotional support, active coping, and religion. Patients used several adaptive coping mechanisms. Those who used problem-solving strategies or maladaptive coping experienced a higher symptom load. People who utilized emotion-focused coping reported less anxiety and depression. These findings emphasize the necessity of evaluating coping methods to aid in symptom management and improve psychiatric care for patients with advanced cancer.

Cancer can be defined as an illness characterized by abnormal cell proliferation, often known as neoplasm. Cancer, the leading cause of death, was responsible for around 7.6 million deaths in 2008, or 13% of all fatalities globally. Children can be affected by a variety of cancers, including leukaemia, neoplasms, osteosarcoma, Wilms tumor, and retinoblastoma. Cancer patients may experience detrimental effects on their physical and psychological health, daily activities and relationships, access to health, spiritual well-being, and sexuality. Holistic nurses should understand how breast cancer patients coped with stress, anxiety, and despair.

Support Systems

There is a growing realisation that the needs of cancer patients and their families extend beyond the medical realm. When toxicities, such as chemotherapy and clinical trials, are completed, health personnel are typically no longer involved with the patient at all. However, there is concern regarding the level of non-medical help that will be required, as well as who should receive such support. Cancer patients are continually bombarded with new information, much of it contradicting. They look for information on whether alternative therapies are beneficial, when treatment decisions must be taken, whether clinical trials are available in their area, and so on. Different people react to a cancer diagnosis in a variety of ways, and treatments that were thought to be beneficial may be ineffective in certain circumstances. There is no unanimity on what kinds of supports would be desirable or wanted to help cancer sufferers help themselves. Patients and relatives primarily seek emotional and psychological assistance; however, this is a vast topic with complex implementation.

Providing extensive psycho-educational support, respite care, basic knowledge of complementary medicine, and tools to engage the help of family and friends would be a specific approach to emotional/psychological support. Cancer care that involves the physical domain can be approached on two levels: practical and isolated. Patients can feel powerful if they can physically aid others with cancer caring. Resources for getting more physically active, assisting family and friends in making appropriate nutritional choices, and so on can all help to foster empowerment. There is plenty of evidence that a healthy lifestyle leads to a longer life expectancy. This information is beginning to spread throughout the community and medical publications.

There is a growing recognition that the needs of cancer patients and their families extend beyond the medical realm. Cancer patients are continuously exposed to new information, most of which is contradictory. They look for information on whether alternative medicines are worth considering, whether clinical trials are available in their area, and so on. However, there is concern regarding the level of non-medical care that will be desired and delivered. One area to consider is the "C" group's community aid services. The C group has deep roots in the community, which are generally maintained

© STM Journals 2026. All Rights Reserved

through volunteer efforts. Respite care and psycho-educational support services are two suggestions. Respite care is clearly a practical option for both patients and carers. This will allow patients to lie back and watch a movie with someone or be taken through a yoga lesson, while still giving carers space to maintain their own sanity.

Palliative Care

Patients with cancer frequently have severe symptoms as the disease advances and following anticancer treatments. Medical and nursing interventions can help reduce these symptoms and improve the patient's quality of life. Palliative care is currently provided by healthcare institutions to help cancer patients lessen or reduce their pain. Palliative care is a method that improves the quality of life of patients and their families dealing with life-threatening illnesses by preventing and alleviating pain and other physical, emotional, and spiritual difficulties. Palliative care is provided to patients at the start of their illness, regardless of disease stage. This results in a higher quality of life for both the patient and their family. Palliative care units in affluent countries frequently have access to more advanced anticancer therapies, such as chemotherapy, radiation, molecular targeted therapies, or surgery. Added to the accumulating body of data is a criticism (Alt-Epping et al., 2011).

Understanding the development process of improper anticancer medicines requires being aware of other professionals' opinions. In surgical oncology, patients awaiting capital surgery may benefit from palliative percutaneous treatments before to curative surgery. Although such interventional radiology may not have a curative objective, it can improve patients' long-term survival by allowing for more comprehensive surgical resection. Over a 5-year period, specialist palliative care services in institutional settings reported oncologists, palliative care teams, geriatricians, and other specialists' perspectives on inadequate anticancer medicines. Holistic care of patients with advanced cancer during a time of ineffectiveness may necessitate interdisciplinary collaboration between specialized palliative care teams and a variety of other experts.

RESEARCH AND FUTURE DIRECTIONS

Cancer is one of the most debated health issues. Millions of individuals throughout the world suffer from cancer. Even in the modern era of biomedical research, it has remained mostly unchanged. A strategy plan to address obstacles in cancer research and treatment is in high demand. There is a need to ponder critically about the probable causes for the widespread cultivation of synthetic medications to combat cancer, which began in the last decade of the nineteenth century; nonetheless, after a century, cancer treatment, particularly primary and complete treatment, remains an unexplored region. Cancer treatments that are both affordable and effective are urgently needed around the world.

It is critical to recognize that a massive effort is underway to develop novel medications that target unique particular protein/catalytic pathways involved in carcinogenesis and tumor growth. Over the previous decade, better scientific tools and platforms have accumulated significantly. Some of them may lead to a greater understanding of cancer biology or, more optimistically, to the start of therapeutic development. However, they are time-consuming operations that will most likely take decades to achieve success. Currently existing cancer treatments, including a wide range of organ toxic chemotherapeutic agents, are fragments of information gleaned after decades of rigorous research, and each therapy has serious and unavoidable adverse effects. For sluggish and ineffective care, exorbitantly priced synthetic agents/cocktail combinations for palliative chemotherapy subject patients to a slew of unknown risks known as cancer-associated suffering. Cancer patients are left with insignificant possibilities for restricted drugs and X-ray-based consolation.

Many of the authorized treatments, as well as many more promising compounds, are currently undergoing rigorous clinical trials. Some new avenues have recently emerged, such as CRISPR-based investigations of the unknown genome for cancer reading, the discovery of tiny organ-targeting molecules such as nucleobase derivatives, bioengineering of responsive mesoporous or vesicular structures, and the manoeuvred exploration of anticytokine and anti-clonal antibodies against some

© STM Journals 2026. All Rights Reserved

undiscovered immune checkpoint proteins. There is still hope built on hope. To develop comprehensive remedies, reverse engineering rationally malignant cells/lesions/tumors requires a significant amount of time, as well as the availability of funding and resources. There is a need and demand for a variety of things, including instant deciphering techniques for personalized drugs, research into carcinogenic discovery, elaborating different avenues of available data regarding cancer detection and drugs, and, most importantly, a strategic research plan for determining the prohibitive point of cancer from benign cells to xenotransplantation during animal testing.

Cancer-related data is made more efficient, allowing each community and individual to draw attention to action, creating a leadership bank of expertize, insight, and resources for planning analysis and action, and connecting with other formal and informal organisations to exchange experiences and resources. Cancer is understood in more ways than just p53 mutations and incorrect methylation. There appears to be a lack of understanding of emergence theories of Bourguignon's chaotic digression equations, Wolpert's modularity theorem, Berenstain's multifractal geometry, and Mendelian properties for inherited carcinogenicity systems and probable causative agents, as well as udRNA and miRNA in malignant transformation, all of which require further investigation.

Current Research Trends

Cancer is one of the most common diseases in the world, and it is one of the few fatal diseases that are considered uncontrollable due to the relentless multiplication of abnormal cells in many organs. Current cancer therapies include surgery, chemotherapy, radiation, targeted therapy, and immunotherapy. Each of these treatments has a different curative potential, which is mostly determined by the type of cancer, stage, and patient performance status. Surgery alone can cure early-stage solid malignancies such as biliary tract cancer and kidney cancer. Nonetheless, most cancer cases are detected at an advanced stage, requiring multimodality techniques to destroy cancer cells and extend lives. Curable patients account for approximately 30% of all cases globally, 50% in the United States, and 70% in Japan, although long-term survival using these approaches is unsatisfactory worldwide.

Solid cancer in its early stages, often with a diameter of ≤2.5 cm, poses a challenge to the healthcare system because to a well-prepared blood circulation and peri-acquisition metastases. With a single excision of the original lesion followed by precise and successful therapy, the cure rate for these cancer patients can surpass 90%. The goal is to minimize invasiveness to reduce problems and improve patients' quality of life. Minimally invasive surgery improves the prognosis of advanced solid cancer by reducing metabolic pressure and enhancing postoperative recovery. The collection of evidence on the benefits of laparoscopic surgery leads to an expansion of its indications.

Surgery is one of the most important components of cancer treatment. The American Cancer Society predicts a large increase in cancer diagnoses, from 2 million in 2015 to 45 million by 2030. Surgery helps to cure solid cancer in its early stages by removing malignant tissue and lymph nodes. However, many cancer cases are identified at the locally advanced or metastatic stage, reducing the effectiveness of curative surgery. Asymptotic benign tumors, such as intracranial meningioma and chromaffin adenoma, limit surgical intervention since they are potentially life-threatening. This emphasizes the development of safe and effective ways for permanently destroying benign tumors. Radiofrequency ablation has previously been approved for the treatment of benign tumors in the liver, thyroid, and breast, and further targeted energy release methods are currently being tested.

Future Therapies

Several promising examples of new therapeutics have appeared in the previous decade, and they are expected to serve as the foundation for the next generation of cancer treatments. Many of these novel medicines are still in the experimental phase. The successful implementation of these new medicines in the clinical context will rely on well-designed Phase I–IV clinical trials, which will take time to confirm. As a result, this article includes more intriguing innovative techniques that are still in the preclinical stage. Many of these emerging novel medicines are based on significant advancements in our understanding of cancer's pathogenetic pathways.

© STM Journals 2026. All Rights Reserved

It is commonly acknowledged that cellular changes that occur during the multistep, multistage process of carcinogenesis produce tumor-initiating cells or cancer stem cells (CSCs), which are responsible for tumor growth and cancer recurrence. CSCs are a small number of tumorigenic cells (1 in ~106) within a heterogeneous population of non-CSCs that cause most tumors. Because of their small number, strong tumorigenicity, and lack of identifying molecules, CSCs are difficult to extract, purify, and cultivate for large-scale functional research utilising current approaches. The most often used CSC markers have been explored in a variety of tumor types; nevertheless, there is insufficient evidence to recommend employing any one marker for CSC investigations. The fixation of commonly used CSC markers as a single phenotype inherently limits the detection of additional potential markers within heterogeneous cell populations in functional investigations for isolation or in vivo animal trials. As a result, there is still a need for a suitable CSC identification molecule that is universally relevant to all types and grades of tumors.

CSCs retain their distinct characteristics by a series of cytogenetic/epigenetic changes in somatic cells caused by the accumulation of DNA mutations directly or indirectly generated by pollutant/stimulus-driven hyper-secretion of activation molecules. The formation of CSCs from normal tissue stem cells includes the misregulation of numerous important signalling pathways. Recent research has made significant strides in understanding the cellular hierarchy involved in CSCs and the therapeutic implications of developmental stage-specific anti-CSC therapy. More effective combinatorial therapies based on developmental stage-specific anti-CSC therapy are likely to be developed and implemented in clinical settings to treat a wide range of malignancies as knowledge of this novel therapy grows.

Ongoing discoveries of new phenotypic or functional fingerprints of cancer initiation/propagation in CSCs may present potential targets for completely different and more effective anti-cancer therapy. Combinatorial natural medicines targeting cellular/swelling regulation, vesicular trafficking, cytoskeletal, and glycolytic enzymes could lead to new diets for cancer patients undergoing chemotherapy or radiation. Additional combinatorial medicines based on newly acquired CSC information will protect saved patients from relapsing during therapy. Further research in this area is expected and desirable.

The Impact of Technology in Cancer Treatment

Cancer is commonly defined as a condition in which aberrant cells divide uncontrollably, destroying body tissue. A tumor is a collection of aberrant cells that arise when a cell is altered by mutagens, resulting in abnormal growth and behavior. Tumors can be benign, meaning they are not cancerous, or malignant, meaning they infect neighboring tissues, enter blood vessels, and spread to other regions of the body. Cancer is a broad term for a variety of disorders characterized by uncontrolled cell division, cell detachment, invasion of surrounding tissues, and the potential transmission of the disease to other organs via lymphatic or circulatory systems. The most common and well-known treatment technique is a combination of surgery, chemotherapy, and radiation therapy. Surgery, if performed early, can increase the chances of long-term survival. Chemotherapy is the employment of chemical agents, medicines, and hormones to eliminate cancer cells. Chemotherapy is not selective, as it affects both normal proliferative cells in bone marrow, gut epithelium, and hair follicles, as well as cancer cells. Chemotherapy-induced bone marrow destruction causes myelosuppression, which leads to haematologic and opportunistic infections. Chemotherapy causes damage to the gut epithelium, resulting in perforation, labelled carcinoembryonic antigen, and peritoneal cavity and abdominal septicaemia. Most solid tumors are radioresistant, and because the treatment window is limited, less than 1% of tumor cells can be destroyed. As a result, protecting normal nearby tissues from radiative damage is critical to maintaining life quality.

Another option is radiation treatment, which kills cancer cells by emitting highly focussed ionising radiation orthogonally. It targets rapidly dividing cells such as hair follicles, gastrointestinal epithelium, bone marrow, and capillary endothelial cells. Tissue hypocellularity causes acute adverse effects such

© STM Journals 2026. All Rights Reserved

as hair loss, gut lining irritation, and opportunistic infections. Early radiation treatment mortality (within 3 to 30 days) is caused by haematopoietic, gastro-intestinal, and cutaneous stem cell compartment depletion, as well as the incidence of severe opportunistic infections that result in septicaemia and multi-organ failure.

CONCLUSION

Cancer has been a dreaded disease from the beginning of humanity since it is impossible to control or contain. Although many of the natural cures accessible in ancient systems of medicine were efficient in curing many types of cancer, after independence, the entire emphasis switched to a chemical-based approach for diagnosis and therapy. This chemical-based paradigm remains the cornerstone of cancer diagnosis and treatment. Surgery, chemotherapy, and radiotherapy are done in conjunction, but they are insufficient to prevent recurrence. By the time a cancer is identified, it has become an issue of containment rather than cure, which is unfortunately the case with modern cancer therapy, when patient safety must undoubtedly take a second seat.

Chemotherapy and radiotherapy have substantial adverse effects because they kill both quickly dividing normal and malignant cells. Immunotherapy techniques aim to either boost nitric oxide levels or limit the amount of angiogenins and growth factors secreted by the tumor. Even if such a strategy could be made to work in vitro, where all of the secreted factors are no longer available to the tumor, it would be a very difficult challenge in vivo because all cells require nitric oxide, angiogenins, and growth factors. It would be like rearranging a deck chair on the Titanic, where most of the cancer cells have already taken a different route to survival modes. Chemotherapy treatment attempts to gently kill cancer cells and, at the very least, diminish the concentration of growing cells; however, chemicals once administered cannot be easily removed since they continue to destroy cells in other parts of the body, causing adverse effects. The greatest way would be to maintain a comparable healthy lifestyle while using natural items for preventive and therapy.

REFERENCES

1. Wang S, Liu Y, Feng Y, Zhang J, Swinnen J, Li Y, et al. A review of cancer curability: Additional efforts for novel therapeutic options are required. Cancer Manag Res. 2019;11:10397–10409.
2. Virani K. A discrete model of cancer tumour growth and treatment effects. New York: City University of New York (CUNY); 2016.
3. Kaul P, Choudhary D, Tiwari AR, Walia R, Sadhu S, Garg PK. A cross-sectional study of the most common myths and misconceptions among cancer patients' carers. J Cancer Educ. 2023;38(3):1031–1037.
4. Souto EB, da Ana R, Vieira V, Fangueiro JF, Dias-Ferreira J, Cano A, et al. Non-melanoma skin cancers: Physiopathology and the significance of lipid delivery systems in novel chemotherapeutic therapies. Pharmaceutics. 2022;14(3):553.
5. Bleloch JS, Ballim RD, Kimani S, Parkes J, Panieri E, Willmer T, et al. Managing sarcoma: Where have we come from and where are we going? Ther Adv Med Oncol. 2017;9(10):637–659.
6. Salama M, Aborehab N, El Mahdy N, Zayed A, Ezzat SM. Nanotechnology in leukaemia: Diagnosis, tailored drug administration, and clinical trials. Pharmaceutics. 2023;15(2):457.
7. Turaliu M, Sava LG, Goan CM, Budu VA. Therapeutic approaches for treating malignant lymphomas of the head and neck. Arch Balk Med Union. 2018;53(3):454–458.
8. Abdullah Z, Zaaba SK, Mustaffa MT, Mohamad CWSR, Mohtar JA. A review of cold atmospheric plasma treatment for melanoma skin cancer. J Telecommun Electron Comput Eng. 2018;10(1–17):125–130.
9. Dasgupta P, Cameron JK, Cramb SM, Trevithick R, Aitken JF, Mengersen K, et al. Geographic and spatial inequalities in the incidence and survival rates of uncommon malignancies in Australia. Cancer Epidemiol. 2023;83:102346.
10. Kondo T. Current and future outlook for patient-derived cancer models in rare cancer research. Cells. 2021;10(1):90.

© STM Journals 2026. All Rights Reserved

11. Koo MM, Swann R, McPhail S, Abel GA, Elliss-Brookes L, Rubin GP, et al. Cancer symptoms and stage at diagnosis: Findings from a cross-sectional population-based study. Lancet Oncol. 2020;21(1):73–79.
12. Zubair M, Wang S, Ali N. Advanced methods for breast cancer classification and diagnosis. Cancers (Basel). 2021;13(11):2852.
13. Khanna D, Khargekar NC, Khanna AK. Implementation of early cancer detection services in India during the COVID-19 pandemic. Asian Pac J Cancer Prev. 2020;21(10):2925–2930.
14. Messadi DV. Diagnostic aids for detecting oral precancerous diseases. Int J Oral Sci. 2013;5(2):59–65.
15. Debela DT, Muzazu SGY, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current viewpoints. J Oncol. 2021;2021:1–13.
16. Collins C, editor. Radiation therapy medical physics review: Delivery, interactions, safety, feasibility, and head-to-head comparisons of the leading radiation therapy techniques. Durham: University of New Hampshire; 2017. Available from: https://scholars.unh.edu/honors/377
17. Kumar S, Choudhary S, Singh N, Setty M. Combination of natural drugs: An emerging trend in cancer chemotherapy. J Drug Deliv Ther. 2012;2(3):111–116.
18. Yang L, Ning Q, Tang S. Recent advances and the next breakthrough in cancer immunotherapy. J Hematol Oncol. 2022;15:130.
19. Leong PP, Seow HF. Cancer immunotherapy: Current developments and uses. Oncology. 2006;70(5):395–405.
20. Seebacher N, Stacy AE, Porter GM, Merlot AM. Clinical trials of targeted and immune-based anticancer treatments. Int J Mol Sci. 2019;20(15):3643.
21. Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Hozhabri Safa S, et al. Recent breakthroughs in non-small cell lung cancer targeted therapy: An update review. Cancers (Basel). 2023;15(5):1396.
22. Imtiaz I, Schloss J, Bugarcic A. A scoping review of traditional and current herbal medications used to treat cancer. J Integr Med. 2024;22(2):89–102.
23. Ahmad A, Ginnebaugh KR, Li Y, Padhye SB, Sarkar FH. Molecular targets of naturopathy in cancer research: A link to modern medicine. Nutrients. 2015;7(5):3219–3249.
24. Chandwani KD, Ryan JL, Peppone LJ, Janelsins MC, Sprod LK, Devine K, et al. Cancer-related stress and complementary and alternative medicine: A review. J Altern Complement Med. 2012;18(10):928–936.
25. Mayden KD. Mind-body therapies: Evidence and implications for advanced oncology practice. Clin J Oncol Nurs. 2012;16(6):670–677.
26. Chasen MR, Dippenaar AP. Cancer nutrition and rehabilitation: The time has arrived. Curr Oncol. 2008;15(5):241–243.
27. Cardoso DH, Muniz RM, Guimarães SRL, Viegas AC, Pinto BK, Laroque MF. Living with cancer: The perspective of oncology patients. Rev Gaucha Enferm. 2013;34(3):111–117.
28. Elsheshtawy EA, Abo-Elez WF, Ashour HS, Farouk O, El Zaafarany MIE. Coping strategies in Egyptian women with breast cancer. Breast Cancer (Dove Med Press). 2014;6:57–62.
29. Dev R, Agosta M, Fellman B, Reddy A, Baldwin S, Arthur J, et al. Coping strategies and symptom burden among patients with advanced cancer. J Pain Symptom Manage. 2023;65(4):e371–e380.
30. Rutledge R, Robinson L. Community-based organisations play crucial roles in providing comprehensive cancer care. Eur J Cancer Care (Engl). 2009;18(6):522–528.
31. Henshall CL, Greenfield SM, Gale NK. Typologies for restructuring relationships in cancer survivorship: Temporal changes in social support and self-management practices. Cancer Nurs. 2018;41(6):E32–E40.
32. Alt-Epping B, Pache S, Lindena G, Nauck F. Anticancer treatments in specialised palliative care: A multicenter survey. Support Care Cancer. 2011;19(12):2061–2067.
33. Upadhyay A. Cancer: An unknown territory; reconsider before proceeding. Indian J Med Ethics. 2020;5(2):135–138.
34. Dembic Z. Anti-tumor drugs and their targets. Molecules. 2020;25(18):4367.

© STM Journals 2026. All Rights Reserved

35. Kalin A. Improving cancer treatment delivery to reduce side effects. New York: Columbia University; 2012.
36. Latha ST. Identifying and isolating bioactive constituents from Gomphrena globosa aerial parts for cancer therapy. Chennai: Tamil Nadu Dr. M.G.R. Medical University; 2013.
37. McKendrick J. Treatment for cancer. Eur J Cancer. 2014;50(1):1–4.

© STM Journals 2026. All Rights Reserved